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Introduction 38
Psoriasis is a chronic inflammatory skin disease with symptoms of well-defined, raised, scaly, red 39 lesions on skin. It is characterized by excessive growth and aberrant differentiation of epidermal 40 keratinocytes. A number of known psoriasis susceptibility loci have been identified 1 , some of 41 which are shared with other chronic inflammatory diseases 2 . Psoriasis also shares pathways with 42 other diseases. For example, the interleukin-23 (IL-23) pathway and nuclear factor-κB (NFκB) 43 pathway are associated with psoriasis 3 , while the IL-23 pathway is a therapeutic target of Crohn's 44 disease 4 , and the dysregulation in the NFκB pathway contributes to Huntington's disease 5 . Despite 45 great progress made over the past few years, the exact causes of psoriasis remain unknown 6 . 46
To discover the disease mechanisms, significant effort has been devoted to analyzing psoriasis 47 gene expression. For example, in a study of small and large plaque psoriasis, microarray gene 48 expression analysis revealed the up-regulation of genes in the IL-17 pathway in psoriasis. But the 49 expression of genes in this pathway of small plaque psoriasis is significantly higher than that of 50 large plaque psoriasis, and negative immune regulators like CD69 and FAS have been found to be 51 down-regulated in large plaque psoriasis. This result suggests that the down-regulation of these 52 negative immune regulators contributes to the molecular mechanism of large plaque psoriasis 53 subtypes 7 . 54
As high-throughput sequencing becomes the mainstream technology, RNA-Seq has also been 55 used for measuring gene expression to gain biological insights of psoriasis. For example, a recent 56 RNA-Seq-based gene expression study of a large number of samples from lesional psoriatic and 57 normal skin uncovered many differentially expressed genes in immune system processes 8 . The co-58 expression analysis based on this dataset detected multiple co-expressed gene modules, including 59 a module of epidermal differentiation genes and a module of genes induced by IL-17 in 60 keratinocytes. This study also discovered key transcription factors in psoriasis and highlighted the 61 processes of keratinocyte differentiation, lipid biosynthesis, and the inflammatory interaction 62 among myeloid cells, T-cells, and keratinocytes in psoriasis. 63
The high resolution of RNA-Seq data allows for study of not only gene expression but also 64 splicing in psoriasis. A recent analysis of psoriasis RNA-Seq data revealed around 9,000 RNA 65 alternative splicing isoforms as a significant feature of this disease 9 . Another study showed that 66 serine/arginine-rich splicing factor 1 (SRSF1) promoted the expression of type-I interferons (IFNs) 67 in psoriatic lesions, and suppression of SRSF1 treated by TNFα in turn suppressed the expression 68 of IFNs 10 . Despite the potentially important role that splicing plays in the mechanism of psoriasis, 69 analyzing alternative splicing in psoriasis has received relatively little attention in the research 70 community. To develop a better understanding of the disease mechanism of psoriasis, this study 71 seeks to perform an integrative analysis to reveal missing information about splicing in psoriasis 72 that will largely complement previous gene expression analysis. 73
To reveal the biological functions of the alternative splicing events in psoriasis, we performed 74 multiple sequence alignment (MSA) between the sequences of mouse and human alternative 75 splicing events, as the conserved splicing events are more likely to play similar roles in both 76 species 11,12 . Our analysis revealed 18 conserved exon-skipping (ES) events between mice and 77 humans. These conserved events are potential candidates for further functional study. 78
To identify the candidate splicing factors (SFs) that may be key regulators of splicing 79 disruption seen in psoriasis, we created a database-called SFMetaDB 13 -of all RNA-Seq datasets 80 publicly available in ArrayExpress 14 and Gene Expression Omnibus (GEO) 15 from gain or loss 81 function studies of SFs in mice. Using the data source from SFMetaDB, we implemented a 82 signature comparison method to infer the critical SFs for psoriasis. The splicing changes in a 83 psoriasis mouse model 16 and the SF perturbation datasets were used to derive the splicing 84 signatures. By comparing the signatures of psoriasis datasets to the splicing signatures of our 85 splicing signature database, we revealed nine candidate SFs that potentially contribute to the 86 regulation of alternative splicing in psoriasis. Genes regulated by such key SFs are involved in a 87 number of critical pathways associated with psoriasis. Our large-scale analysis provides candidate 88 targets for the biology research community to experimentally test the role of splicing in psoriasis. 89
These results underlie the importance of completing the transcriptome landscape at the splicing 90 level and pave the way for more detailed mechanistic studies of psoriasis in the future. 91
92
Results 93
Revealing large-scale changes in alternative splicing by analyzing RNA-Seq data from 94 psoriasis mouse model and human skin 95
To investigate the role of the splicing process in psoriasis, a psoriasis mouse model was studied 96 first to detect splicing changes. In this mouse model, the gene Tnip1 was knocked out 16 . Notably, 97 TNIP1 (the homologous gene of Tnip1) in humans is found in a psoriasis susceptibility locus 17 . It 98 has been shown that Tnip1 knockout (KO) mice exhibit macroscopical psoriasis-like phenotypes, 99 such as redness and scaling, and microscopical psoriasis-like phenotypes, such as epidermal 100 thickening, elongated rete-like ridges, papillomatosis, retention of nuclei within corneocytes, and 101 infiltrations with different immune cell types 16 . To reveal splicing changes, the Dirichlet 102 Multinomial (DMN) regression 18 was used to analyze the dataset from the Tnip1 KO mouse model. 103
Benjamini-Hochberg-adjusted 19 p-value and the percent sliced in (PSI, Ψ) were estimated for 104 seven types of splicing events (see Methods). Under ΔΨ > 0.05 and < 0.05, a total of 609 105 differential alternative splicing (DAS) events were identified (Table S1 ). Figure 1a shows the 106 number of DAS events for seven splicing types in the mouse model. To verify that the Tnip1 KO 107 mouse model recapitulated the main splicing features in human psoriasis, we performed a DAS 108 analysis using RNA-Seq data from psoriasis patients and controls 8 . This DAS analysis identified 109 606 DAS events ( ΔΨ > 0.05 and < 0.05) (Table S1 ). Figure 1b Our DAS results revealed many significant splicing events in the psoriasis mouse model. 114 To identify the most critical splicing changes in psoriasis, we conducted a splicing conservation 134 analysis to reveal the splicing changes common to both the Tnip1 KO mouse model dataset and 135 the human psoriasis dataset. By mapping mouse and human gene symbols using HomoloGene 23 , 136 we detected 89 homologous genes with DAS events in both mice and humans (Figure 4) . The 137
Fisher's exact test showed significant enrichment of the common homologous genes with = 138 1.7×10 ./0 (see Methods). This supports the conclusion that there is commonality in splicing 139 underlying psoriasis in both mice and humans. 140
To further characterize the conservation of splicing in mice and humans, we compared the 141 isoform sequences between them. By the splicing conservation analysis at the isoform level (see 142
Methods), we ended up with 24 homologous genes with conserved isoform sequences for the 143 common splicing events in human and mouse gene annotation (Supplemental Data S1, Table  144 S3). The high proportion of conserved isoform sequences for the common splicing events (24 of 145 33) suggested feasible and promising conservation of splicing changes between the Tnip1 KO 146 mouse model dataset and the human psoriasis dataset (see the representative MSA of 147 Exoc1/EXOC1 in Supplemental Document S1). 148
To identify the splicing features in psoriasis, we further evaluated whether the common 149 splicing events were conserved in the same isoform between the Tnip1 KO mouse model dataset 150 and the human psoriasis dataset. Specifically, we checked whether the splicing events shared the 151 same inclusion pattern of variable exons in mouse and human. We ended up with 18 alternative 152 splicing events conserved in the same isoform, which means that the splicing events have more or 153 less inclusion of variable exons in the same way between the two species ( Table 1) . The 154 corresponding 18 homologous genes with conserved alternative splicing events include ABI1, 155 ARHGAP12, ATP5C1, CTTN, DNM1L, EXOC1, FBLN2, FNBP1, GOLGA2, GOLGA4, MYH11, 156 MYL6, MYO1B, PAM, SEC31A, SLK, SPAG9, and ZMYND11. The MSA results for the 18 157 common spliced genes can be found in Supplemental Data S1 and Table S3 . Of the 18 conserved 158 splicing events, eight were largely spliced in both species, with over 10% PSI differences (Table  159 1). Figure 2 and Figure 1S show the conserved splicing events in Exoc1/ EXOC1, Fbln2 /FBLN2, 160
Fnbp1/FNBP1, and Atp5c1/ATP5C1 using the UCSC genome browser tracks 20 . Our conservation 161 analysis identified the 18 conserved splicing events, suggesting that the splicing features in the 162 psoriasis mouse model dataset can be recapitulated in the human psoriasis dataset, and further, the 163 18 conserved splicing events can be promising targets to follow to study the splicing mechanism 164 in psoriasis. 165
Revealing candidate splicing factors regulating splicing in psoriasis by splicing signature 166 analysis in mouse 167
To further elucidate the splicing mechanism in psoriasis, we conducted SF screening to discover 168 the candidate SFs that may regulate large-scale splicing events in psoriasis. Because a great 169 number of splicing events are discovered in mouse psoriasis datasets, we hypothesize that SFs may 170 play critical roles in the regulation of these events. To screen for the candidate SFs, we manually 171 curated a list of RNA-Seq datasets with gain-or loss-of-function of mouse SFs 13 (see Methods). 172
Using the datasets in SFMetaDB, we systematically compared the splicing changes in the psoriasis 173 mouse model dataset with the effects of SF perturbation using a splicing signature comparison 174 workflow (Figure 5 , see Methods). Our splicing signature comparison approach screened the SF 175 perturbation datasets related to a total 31 SFs for splicing regulators in the mouse psoriasis dataset, 176
where nine SFs showed significant overlapping splicing changes in psoriasis, including NOVA1, 177 PTBP1, PRMT5, RBFOX2, SRRM4, MBNL1, MBNL2, U2AF1, and DDX5 (Table S4) , which 178 are potential regulators responsible for splicing changes in psoriasis. 179
Confirming the key splicing regulators in humans 180
To confirm the importance of these nine SFs in mice, we performed a similar splicing signature 181 comparison analysis in humans. Using the human homologous symbols of these nine mouse SFs, 182 we curated on GEO 15 the human RNA-Seq datasets with these genes perturbed. Our curation 183 resulted in four datasets for three of nine human SFs-GSE59884 24 and GSE69656 25 for PTBP1, 184 GSE66553 for U2AF1, and GSE76487 26 for MBNL1. The splicing signature comparison analysis 185 (Figure 5, see Methods) using splicing signatures from the human psoriasis dataset and the four 186 datasets of the three human SF perturbation showed significantly overlapped splicing changes 187 between the human psoriasis dataset and the SF perturbation datasets of three human SFs-i.e., 188 PTBP1, U2AF1, and MBNL1 (Table S4) . These results suggest the important role of these three 189
SFs in potentially regulating splicing in psoriasis. 190
Revealing potential candidate SFs that regulate splicing in psoriasis using conserved splicing 191
events in SF perturbation datasets 192
To identify the potential SFs that regulate the conserved splicing events in psoriasis, we 193 investigated the consistency of regulation direction of splicing events in the mouse/human dataset 194 and the SF perturbation datasets. The 18 conserved ES events were significantly conserved in the 195 Tnip1 KO mouse model dataset and the human psoriasis dataset, indicating the key spliced genes 196 in psoriasis. Upon checking whether the splicing events were positively/negatively regulated by 197 the SF in the same way in the SF perturbed datasets and the psoriasis datasets (Figure 5b) Previous studies have shown the potential roles of splicing in the pathogenesis of psoriasis. 213
For example, an isoform of TRAF3IP2 with a mutation may cause the formation of psoriasis. The 214 TRAF3IP2 gene is an essential adaptor in the IL-17 signaling pathway contributing to psoriasis. 215
The exon-2-excluded isoform of TRAF3IP2 loses its ability to transduce IL-17 signals to regulate 216 downstream gene expression when there is a specific amino acid substitution at the N terminus of 217 this isoform. The expression of this mutated isoform may promote overproduction of IL-22 and 218 IL-17. Thus, alternative splicing with this mutation predisposes carriers to the susceptibility of 219 psoriasis 27 . 220
As another example, the expression of an isoform of the Il15 gene may inhibit the proliferation 221 of keratinocyte in mouse skin. IL-15 is a cytokine that stimulates the proliferation of T-cells and 222 natural killer cells. The exon-7-excluded isoform of Il15 is minimally expressed in normal skin, 223 but its expression can be induced by a point mutation in exon 7 of Il15. The expression of this 224 isoform can reduce keratinocyte activation and inhibit infiltration of neutrophil into the dermis, 225 producing a less-inflammatory response. Because Il15 is within the PSORS9 psoriasis 226 susceptibility locus, this work suggested a potential alternative splicing mechanism by which Il15 227 contributes to the pathogenesis of psoriasis 28 . 228
Computational analysis has been shown to be a feasible and effective way to generate novel 229 biological hypotheses. For example, a network reconstruction method was used to infer MPZL3 230 as a key factor in the mitochondrial regulation of epidermal differentiation 29 . As another example, 231 a gene regulatory network analysis was applied to identify MAF and MAFB as the key 232 transcription factors in epidermal differentiation 30 . We performed DAS analysis on the publicly 233 available psoriasis mouse model dataset 16 . The large-scale DAS changes in the Tnip1 KO samples 234 compared with wild-types provided a feasible discovery of the key splicing features in psoriasis. 235
To facilitate the discovery of the key splicing events in psoriasis, we also performed DAS analysis 236 on a publicly available human psoriasis dataset 8 . The sharing of a large number of differential 237 splicing events between the two species underlies the potential importance of splicing in psoriasis. 238
The subsequent MSA analysis of the isoform sequences strengthened the discovery of the 239 conserved splicing events in psoriasis. In addition, the splicing signature comparison workflow 240 was applied to infer the potential candidate SFs that may regulate splicing changes in psoriasis. 241
These computational analyses suggest the critical role that alternative splicing may play in 242 psoriasis. 243
Our results suggest the potential contribution of selected splicing events in the mechanism of 244 psoriasis. From MSA analysis, we detected 18 conserved genes sharing a common splicing pattern predictions is expected to further strengthen the support of our discovery. The 18 conserved 297 splicing events identified in our DAS analysis can be good candidates for experimental validation. 298
In addition, in vivo experiments of the identified splicing regulators may provide a better 299 understanding of how alternative splicing is disrupted in psoriasis. 300
In conclusion, our DAS analysis suggests a number of splicing events related to psoriasis 301 conserved in mice and humans, as well as SFs that may be responsible for the regulation of splicing 302 in psoriasis. These conserved splicing events and potential candidate SFs pave the way for the 303 research community to study the role of splicing in psoriasis. The computational DAS analysis is 304 a feasible and efficient way to generate biological hypotheses about the role of splicing in psoriasis. 305
Methods 306

Differential alternative splicing analysis using RNA-Seq data 307
To identify the DAS events, we performed DAS analysis for the Tnip1 KO mouse model 308 dataset (GSE85891), where the Tnip1 KO mice and controls were treated for two days with 309 imiquimod (IMQ) 16 , and for the human psoriasis dataset (GSE54456), where the human lesional 310 psoriatic and normal skins established large-scale gene expression data 8 . We first aligned the raw 311
RNA-Seq reads to mouse (mm9) or human (hg19) genomes using STAR (version 2.5.1b) 45 with 312 default settings, and only uniquely mapped reads were retained for further analysis. The number 313 of reads for each exon and exon-exon junction in each RNA-Seq file was computed by using the 314 Python package HTSeq 46 with the annotation of the UCSC KnownGene (mm9 or hg19) 315 annotation 47 . DMN was used to model the counts of the reads aligned to each isoform of each 316 event 18 , and the likelihood ratio test was used to test the significance of the changes in alternative 317 splicing between psoriasis samples and controls 48 . We calculated the q-values from the p-values 318 in the likelihood ratio test by the Benjamini-Hochberg procedure 19 . The DAS events are classified 319 into seven splicing types: Exon skipping (ES), alternative 5' splice sites (A5SSs), alternative 3' 320 splice sites (A3SSs), mutually exclusive (ME) exons, intron retention (IR), alternative first exons 321 (AFEs) and alternative last exons (ALEs). In addition, PSI was used to evaluate the percentage of 322 the inclusion of variable exons relative to the total mature mRNA in the splicing events 49 . The PSI 323 was originally defined for ES events. Here, its definition is expanded to describe the changes in 324 splicing of all the splicing types in our DAS analysis. Specifically, the splicing event types ES, 325 A5SS, A3SS, ME, and IR involve two isoforms where one isoform is longer. We calculated the 326 PSI as the percentage usage of the longer isoform compared with both isoforms. For the splicing 327 events AFE and ALE, we calculated PSI as the percentage of usage of the proximal isoform (the 328 isoform with the variable exon closer to the constitutive exon) relative to both isoforms of the 329 event. The DAS events are identified under ΔΨ > 0.05 and < 0.05. 330
Gene ontology analysis 331
To examine the biological functions of the genes in the Tnip1 KO mice and the human psoriasis 332 dataset, GO analysis was performed to screen for the enriched GO terms using Fisher's exact test 50 333 with the null hypothesis H 0 : log odds ratio < 1. In the test of enriched GO terms for the genes with 334 DAS events, these genes were taken as the foreground, and the expressed genes were taken as the 335 background. To reveal the enriched GO terms for differentially expressed genes, specifically up-336 regulated genes were taken as the foreground and expressed genes were taken as the background. 337
The estimated log odds ratio was also retained for overlapped GO terms. Enriched GO terms were 338 identified under p-value < 0.05. 339
Splicing conservation analysis 340
To reveal the biological function of DAS events in psoriasis, we performed splicing 341 conservation analysis between mice and humans. We first checked whether the homologous genes 342 between the two species both had the DAS events. By mapping the human gene symbol to the 343 mouse homologous gene symbol using HomoloGene 23 , we constructed a contingency table  344 consisting of the counts of the homologous genes in both species with DAS events or in only one 345 species with DAS events. Taking the homologous genes expressed in both mice and humans as 346 the background genes, the Fisher's exact test was used to test the enrichment of common 347 homologous genes with DAS events in both species. 348
Additionally, we compared the isoform sequences between mice and humans. Within the 89 349 homologous genes with DAS events, 33 showed ES events in both species. To investigate the 350 conservation of splicing changes in these 33 genes, we performed MSA analysis of the ES events 351 in these genes. We first extracted the two isoform sequences that cover each of the ES events-352 i.e., the upstream and downstream exons in the event are included in both isoforms, but the variable 353 exon is included in only one of the isoforms. Within each homologous gene, we compared all the 354 mouse-human splicing event pairs. In each comparison, we constructed an MSA of the translated 355 protein sequences or the predicted mRNA sequences of the extracted isoforms in mice and humans 356 using MAFFT 51 . For the coding events, we constructed the MSA for the translated protein 357 sequences. Alternatively, for the events with noncoding isoforms, we built the MSA for the 358 predicted mRNA sequences. The MSA results between the mouse and human isoforms revealed a 359 commonality of splicing events between mice and humans. 360
Mouse splicing factor perturbation database 361
To screen for the candidate SFs that may regulate splicing in psoriasis, we curated a set of 362 mouse RNA-Seq datasets with perturbed SFs. Our curated datasets were deployed as a database 363 called SFMetaDB 13 , which hosts the full mouse RNA-Seq datasets with perturbed SFs (knocked-364 out/knocked-down/overexpressed). To curate the mouse SF perturbation database in SFMetaDB, 365
we extracted 315 RNA SFs in GO (accession GO:0008380) for the mice 50 . For each SF, we used 366 the gene symbol to search against ArrayExpress 14 for mouse RNA-Seq datasets. For the retrieved 367 results from ArrayExpress, we performed manual curation of the dataset to make sure the SF was 368 perturbed in the dataset. We ended up with 34 mouse RNA-Seq datasets for the perturbation of 31 369
SFs. These 34 SF perturbation datasets provided the precious raw data for us to induce the 370 candidate SFs that regulate splicing in psoriasis. 371
Splicing signature-based connectivity map 372
To identify the candidate SFs that regulate splicing events in psoriasis, we first determined 373 whether the expression of SFs increased or decreased in the Tnip1 KO mouse dataset and the 374 human psoriasis dataset using the following procedure. The raw RNA-Seq reads were aligned to 375 mouse/human genome using STAR, the same as the DAS analysis. The uniquely mapped reads 376 were used to calculate the read-counts for each gene against the UCSC KnownGene annotation 377 (mm9/hg19). A table of read-counts for all the genes and all the samples was created and 378 normalized by DESeq 52 . The fold change calculated from this normalized count table was used to 379 determine whether the expression of an SF increased or decreased. 380
Then, we checked how the splicing events were regulated by the SFs in the SF perturbation 381 datasets by comparing these splicing events with the events in the psoriasis datasets. For example, 382 if 1) a splicing event was positively regulated by an SF according to an SF perturbation dataset-383 i.e., the inclusion of the variable exon of the event was increased (Figure 5a ) upon the 384 overexpression of the SF or the inclusion of the variable exon of the event was decreased upon the 385 knock-down/knock-out of the SF in the SF perturbation dataset (Figure 5b) , and 2) the same 386 variable exon was more included in psoriasis along with an increased expression of the SF or the 387 same variable exon was less included in psoriasis along with a decreased expression of the SF, this 388 consistency between 1) and 2) suggests that the event is likely regulated by the SF in psoriasis. If 389 this consistency holds across a significantly large number of events, then the SF is likely a key 390 factor responsible for the regulation of large-scale splicing changes in psoriasis. This consistency 391 comparison approach was also used in CMap, a gene expression signature comparison method that 392 has been widely used to detect the consistency between the gene expression signatures of a disease 393 and the small-molecule or drug-treated samples 53 . Such a signature comparison method based on 394 gene expression is powerful because some of the predictions have been validated in vivo 54 . 395
However, most signature comparison approaches mainly focus on gene expression data and fail to 396 detect fine-tuning of gene expression by splicing. To obviate the drawback in CMap, we applied a 397 splicing signature-based comparison method using splicing changes in the SF perturbation 398 datasets and the psoriasis datasets (Figure 5c ). We first calculated the splicing signatures for the 399 34 SF perturbation datasets, where +/indicates that an event is positively/negatively regulated 400 by the given SF of the dataset and 0 indicates that no evidence exists that the event is regulated by 401 the SF. Another signature vector made of +/-/0 was used to characterize the relation of an SF 402 and the events in the psoriasis dataset. By comparing a signature from the SF perturbation dataset 403 with a signature from the psoriasis data, a 3×3 contingency table was tabulated with rows and 404 columns named +/-/0 and was used to see whether the two signatures match each other. To 405 further check for the direction of the consistency, we collapsed the 3×3 table into two 2×2 tables 406 so that the enrichment of + + events and -events, respectively, could be tested using Fisher's 407 exact test (Figure 5c ). The SFs with significantly enriched + + events and -events are the 408 candidate SFs that regulate the splicing in psoriasis. 409
Data availability 410
All data generated or analyzed during this study are included in this published article. 411 To investigate the genes with DAS events, we ended up with 667 genes in the Tnip1 KO mouse 583 model dataset and 607 genes in the human psoriasis dataset. Mapping the human gene symbols to 584 mouse homologous genes using HomoloGene resulted in 89 common homologous genes with 585 DAS events in both species. Alternatively, 578 genes have DAS events in mice but not humans. 586
FIGURE LEGENDS 558
On the other hand, 518 genes have DAS events in humans but not mice. Taking 12,233 587 homologous genes expressed in both species as the background genes, the Fisher's exact test 588 showed significant enrichment of the common homologous genes with = 1.7×10 ./0 . 589 The ΔΨ s are of the same negative signs, meaning psoriatic samples have more exclusion for the 614 splicing events in DMKN/Dmkn of both species. However, the isoform with more inclusion of the 615 variable exon in the human (hs_inc) is conserved with the isoform with more exclusion of variable 616 exon in the mouse (mm_excl). Therefore, the event is not conserved. 617 b The ΔΨ s are of the same negative signs, meaning psoriatic samples have more exclusion for the 618 splicing events in POSTN/Postn of both species. However, the isoform with more inclusion of the 619 variable exon in the human (hs_inc) is conserved with the isoform with more exclusion of variable 620 exon in the mouse (mm_excl). Therefore, the event is not conserved. 
